22 May 2013
Keywords: lilly, enzastaurin, enters, ph, iii, nhl, trials
Article | 05 June 2006
US drug major Eli Lilly says it has initiated a Phase III clinical trial assessing the anticancer agent enzastaurin, an ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 June 2006
29 May 2006
21 May 2013
© 2013 thepharmaletter.com